Use of RXR agonists and taxanes in the treatment of HER2+ cancers
A combination of taxanes and RXR agonists, possibly with thyroid hormone, addresses the limitations of current cancer therapies by enhancing treatment efficacy and reducing side effects through synergistic cancer growth inhibition.
Patent Information
- Application Number
- JP2024534052
- Authority / Receiving Office
- JP · JP
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2021-12-07
- Filing Date
- 2022-12-07
- Publication Date
- 2024-11-21
- Estimated Expiration
- Not applicable · inactive patent
AI Technical Summary
Current cancer treatments, including retinoids like bexarotene, face limitations due to RAR activation reducing their effectiveness, and it is challenging to determine which treatments should be used for specific cancer indications and their effective combinations.
A combination therapy involving a taxane and an RXR agonist, such as IRX4204, is administered to patients with cancer, potentially enhanced by thyroid hormone, to synergistically inhibit cancer growth, even in cases of less than complete response to initial treatments.
The combination of taxanes and RXR agonists demonstrates synergistic effects in inhibiting cancer growth, offering improved therapeutic outcomes with reduced toxicity and side effects compared to individual treatments.
Smart Images

Figure 2024543621000021 
Figure 2024543621000022 
Figure 2024543621000023
Abstract
Description
[Technical field]
[0001] (CROSS REFERENCE TO RELATED APPLICATIONS) This application claims priority to U.S. Provisional Application No. 63 / 286,986, filed December 7, 2021, the entire contents of which are incorporated herein by reference.
[0002] (Field) This application relates to a combination of an RXR agonist and a taxane to inhibit Her2 + Related to methods of treating cancer.
[0003] (STATEMENT REGARDING FEDERALLY SPONSORED RESEARCH) This invention was made with United States government support under Grant No. HHSN261201500018I from the National Institutes of Health. The United States government has certain rights in the invention. [Background technology]
[0004] Compounds having retinoid-like biological activity are well known in the art and are described in numerous United States patents, including, but not limited to, U.S. Patent Nos. 5,466,861, 5,675,033, and 5,917,082, all of which are incorporated herein by reference. Preclinical studies suggest that selective activation of the retinoid X receptor (RXR), which regulates functions related to differentiation, inhibition of cell proliferation, apoptosis, and metastasis, by RXR agonists (rexinoids) is useful in the treatment of a variety of diseases associated with biochemical functions regulated by RXR.
[0005] For example, TARGRETIN® (bexarotene), a retinoid X receptor (RXR) agonist that also has retinoic acid receptor (RAR) agonist activity, has been approved by the U.S. Food and Drug Administration for oral and topical treatment of cutaneous manifestations of cutaneous T-cell lymphoma in patients refractory to at least one prior systemic therapy. TARGRETIN® has shown promising results in multiple Phase II trials in non-small cell lung cancer (NSCLC). However, a pivotal Phase III clinical trial failed to demonstrate improved survival. One reason for the limited success of bexarotene may be that activation of RAR reduces its efficacy as an anticancer drug. Thus, more selective RXR agonists may hold more promise.
[0006] Cancer treatments are constantly evolving, becoming more specialized and sophisticated. Early non-surgical cancer treatments generally targeted rapidly dividing cells, which are more sensitive to radiation and chemical aggression. Gradually, more specific and generally less toxic treatments have been developed. Some treatments have broad applicability, such as immune checkpoint inhibitors or rexinoids. Others target cancers expressing specific antigens or other biomarkers involved in the control of proliferation or differentiation, including many monoclonal antibodies and kinase inhibitors. There is also a role for cytotoxic drugs in cancer treatment. However, as the number of cancer treatments increases, it becomes more difficult to determine which treatments to apply to which indications and effective combinations of treatments. [Prior art documents] [Patent documents]
[0007] [Patent Document 1] U.S. Pat. No. 5,466,861 [Patent Document 2] U.S. Pat. No. 5,675,033 [Patent Document 3] U.S. Pat. No. 5,917,082 Summary of the Invention [Means for solving the problem]
[0008] In this disclosure, Her2 + An improved method for treating cancer, comprising administering to a patient a therapeutically effective amount of Her2 + Disclosed is a method of treatment comprising treating a patient with a tumor with a combination of a taxane and an RXR agonist that can inhibit the growth of cancer.In some embodiments, the combination of treatment further comprises thyroid hormone.
[0009] One embodiment is Her2 + A method of treating a patient with cancer, comprising administering to the patient an RXR agonist of formula I, or a pharma- ceutically acceptable salt thereof, [ka] In the formula, R is H or lower alkyl having 1 to 6 carbon atoms; Patients must have received, are receiving, or are scheduled to receive a taxane; This is the method.
[0010] One embodiment is Her2 + A method of treating a patient with cancer, comprising administering an RXR agonist of formula I or a pharma- ceutical acceptable salt thereof and a taxane; [ka] In the formula, R is H or lower alkyl having 1 to 6 carbon atoms. This is the method.
[0011] One embodiment is a method for treating a Her2+ agonist receiving treatment with an RXR agonist of formula I or a pharma- ceutical acceptable salt thereof. + 1. A method of treating a patient with cancer, comprising: [ka] In the formula, R is H or lower alkyl having 1 to 6 carbon atoms; There is evidence of a treatment effect of less than complete response, Continuing treatment with an RXR agonist and initiating treatment with a taxane. This is the method.
[0012] One embodiment is a method for treating Her2 + 1. A method of treating a patient with cancer, where there is evidence of less than a complete response, comprising continuing treatment with a taxane and initiating treatment with an RXR agonist of formula I, or a pharma- ceutical acceptable salt thereof; [ka] In the formula, R is H or lower alkyl having 1 to 6 carbon atoms. This is the method.
[0013] One embodiment is Her2 + A method of treating a patient with cancer, comprising administering to the patient an RXR agonist of formula I, or a pharma- ceutically acceptable salt thereof, [ka] In the formula, R is H or lower alkyl having 1 to 6 carbon atoms; the patient has received, is receiving, or will receive a method for binding tubulin and inhibiting microtubule disassembly, for blocking metaphase spindle formation, or for inducing apoptosis by blocking Bcl-2-mediated inhibition of apoptosis; This is the method.
[0014] One embodiment is Her2 + A method of treating a patient with cancer, comprising administering an RXR agonist, wherein the patient has received, is receiving, or will receive a taxane.
[0015] For any of the above aspects, some embodiments further include administering a thyroid hormone.
[0016] For any of the above aspects, in some embodiments, the compound of formula I or the method of activating an RXR / Nurr1 heterodimer receptor or the rexinoid method of inhibiting tumor growth is a compound of formula II. [ka]
[0017] For any of the above aspects, in some embodiments, the taxane is paclitaxel.For any of the above aspects, in some embodiments, the taxane is docetaxel.
[0018] For any of the above aspects, in some embodiments, Her2 + The cancer is gastroesophageal cancer, ovarian cancer, gastric cancer, lung adenocarcinoma, uterine cancer (e.g., serous endometrial cancer), or salivary duct cancer.
[0019] For any of the above aspects, in some embodiments, the combination of the taxane and the RXR agonist has a proliferation inhibitory effect that is greater than the additive inhibitory effect of each of the taxane and the RXR agonist alone.
[0020] For any of the above aspects, some embodiments further involve administration of an additional anti-cancer drug.
[0021] One embodiment is a combination of a taxane and a compound of formula I. [Brief description of the drawings]
[0022] [Figure 1] FIG. 1 is a three-dimensional plot depicting the growth inhibitory effects of IRX4204 and paclitaxel, alone and in combination, on the breast cancer cell line AU565. [Diagram 2]Figure 2 shows a plot of Combination Index (CI) versus Fraction Affected (Fa) for the growth inhibitory effect of IRX4204 and paclitaxel, alone and in combination, on the breast cancer cell line AU565. This is the same data as shown in Table 1. Each cluster of data points represents one concentration of paclitaxel, and each point in the different clusters represents a different concentration of IRX4204 (2.5 nM, 5.0 nM, and 10.0 nM paclitaxel, respectively, in red (dark gray), orange (gray), and yellow (light gray)). [Diagram 3] FIG. 3 is a three-dimensional plot depicting the growth inhibitory effects of IRX4204 and paclitaxel, alone and in combination, on SkBr3 cells, a breast cancer cell line. [Figure 4] Figure 4 shows a plot of Combination Index (CI) versus Fraction Affected (Fa) for the growth inhibitory effect of IRX4204 and paclitaxel, alone and in combination, on the breast cancer cell line SkBr3. This is the same data as shown in Table 1. Each cluster of data points represents one concentration of paclitaxel, and each point in the different clusters represents a different concentration of IRX4204 (2.5 nM, 5.0 nM, and 10.0 nM paclitaxel, red (dark gray), orange (gray), and yellow (light gray), respectively). DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS
[0023] There are a large number of drugs that have shown potential for cancer treatment in the laboratory and / or clinic, and the number is ever increasing. Despite this, cancer remains a difficult disease to treat and control. Combining drugs may improve prognosis, but it is difficult to predict which of the myriad possibilities will actually lead to improved efficacy in which types of cancer. Disclosed herein are Her2 +It is a combination of a taxane and an RXR agonist that act synergistically together to inhibit the growth of cancer cells.
[0024] Taxanes and RXR agonists inhibit Her2 + The method of treating cancer includes various aspects. Cancer may be initially treated with one of these agents, and then the treatment regimen is amended to include the other. In one aspect, the taxane is administered first, and then the administration of the RXR agonist is added to the treatment regimen. In another aspect, the RXR agonist is administered first, and then the administration of the taxane is added to the treatment regimen. In some embodiments of these aspects, the amendment to add the second agent may be made because the treatment with a single agent is insufficient in some way. That is, the cancer may have continued to progress, or some result less than a complete response, such as stable disease or partial response, is obtained.
[0025] In some embodiments, treatment may be initiated with one agent with the intention of beginning administration of the other agent at a later time. In some embodiments, treatment with both agents is initiated in the same time frame. In some such embodiments, the first administration of the second agent is administered prior to the second administration of the first agent. In all embodiments, the patient receives both agents on overlapping administration schedules over a period of time, such that the effects of both agents overlap in time.
[0026] Synergistic effects, which can be achieved with appropriate dose selection, can be important for obtaining improved responses to therapy. In another embodiment, a similar response is obtained, but fewer side effects or toxicities are experienced, due to the use of lower doses of one, the other, or both agents.
[0027] In some embodiments, thyroid hormone is also administered. It has been observed that the use of thyroid hormone in combination with IRX4202 increases the physiological or therapeutic effect compared to that produced by the use of each agent alone. This effect is not the same as reversing the hypothyroidism that may be induced by high doses of IRX4204. Typically, a dose of 10 mg / day of IRX4204 free acid in adult administration produces a therapeutic effect without producing hypothyroidism. A dose of 20 mg / day of IRX4204 free acid in adult administration may produce moderate hypothyroidism in some individuals.
[0028] (RXR agonist) Preclinical studies suggest that selective activation of the retinoid X receptor (RXR), which regulates functions related to differentiation, inhibition of cell proliferation, apoptosis, and metastasis, by RXR agonists (rexinoids) may be useful in treating a variety of diseases associated with biochemical functions regulated by RXR.
[0029] Retinoic acid receptors (RAR) and RXR and their cognate ligands function by different mechanisms of action. The term "RAR" as used in this disclosure means one or more of RARα, RARβ or RARγ. The term "RXR" as used in this disclosure means one or more of RXRα, RXRβ or RXRγ. RAR biomarkers are characteristic biological, biochemical or biologically derived indicators that indicate RAR activity in patients. RAR biomarkers include, but are not limited to, CYP26 levels, CRBPI levels, and the like, and combinations thereof.
[0030] In some embodiments, RAR activation threshold refers to one or more of CYP26 levels increased by 25% above baseline and CRBPI levels increased by 25% above baseline. RAR forms heterodimers with RXR, and these RAR / RXR heterodimers bind to specific response elements in the promoter regions of target genes. Binding of RAR agonists to the heterodimeric RAR receptors activates the transcription of target genes and induces retinoid action. RXR agonists of the present disclosure do not activate RAR / RXR heterodimers. Because activation of transcription by ligand binding occurs only with non-RXR proteins (e.g., RAR), and not with RXR, RXR heterodimer complexes such as RAR / RXR can be referred to as non-permissive RXR heterodimers.
[0031] RXR also interacts with nuclear receptors other than RAR, and RXR agonists may induce some of their biological effects by binding to such RXR / receptor complexes. Because activation of transcription by ligand binding can occur at RXR, other receptors, or both receptors, these RXR / receptor complexes can be referred to as permissive RXR heterodimers. Examples of permissive RXR heterodimers include, but are not limited to, peroxisome proliferator-activated receptor / RXR (PPAR / RXR), farnesyl X receptor / RXR (FXR / RXR), nuclear receptor-associated 1 protein (Nurr1 / RXR), and liver X receptor / RXR (LXR / RXR). RXR can also form RXR / RXR homodimers and be activated by RXR agonists to induce rexinoid effects. RXR also interacts with proteins other than nuclear receptors, and ligand binding to RXR in such protein complexes can also induce rexinoid effects. Due to these differences in mechanism of action, RXR agonists and RAR agonists induce different biological effects, and even if they mediate similar biological effects, they do so through different mechanisms. Furthermore, the undesirable side effects of retinoids, such as proinflammatory reactions or mucocutaneous toxicity, are mediated by the activation of one or more RAR receptor subtypes. In other words, the biological effects mediated through the RXR pathway do not induce proinflammatory reactions and therefore do not result in undesirable side effects.
[0032] Thus, aspects of the present disclosure provide, in part, RXR agonists. As used in this disclosure, the term "RXR agonist" is synonymous with "selective RXR agonist" and refers to a compound that selectively binds to one or more RXR receptors, such as RXRα, RXRβ, or RXRγ, in a manner that induces gene transcription through RXR response elements. As used in this disclosure with respect to RXR agonists, the term "selectively binds" refers to an RXR agonist that does not substantially bind to non-target receptors, such as RARα, RARβ, or RARγ, and that the RXR agonist differentially binds to intended target receptors, such as RXRα, RXRβ, or RXRγ. In some embodiments, the term "RXR agonist" includes esters of RXR agonists.
[0033] For each of the disclosed embodiments, the RXR agonist can be a compound having the structure of Formula I, or a pharma- ceutically acceptable salt thereof: [ka] R is H or lower alkyl having 1 to 6 carbon atoms.
[0034] The present disclosure also discloses esters of RXR agonists. The esters may be derived from the carboxylic acid at C1, or the esters may be derived from a carboxylic acid functionality at another site on the molecule, such as the phenyl ring. Without intending to be limiting, the esters may be alkyl esters, aryl esters, or heteroaryl esters. The term "alkyl" has the meaning commonly understood by those skilled in the art and refers to a linear, branched, or cyclic alkyl moiety. C 1~6Alkyl esters are particularly useful, where the alkyl portion of the ester has 1 to 6 carbon atoms, including, but not limited to, methyl, ethyl, propyl, isopropyl, n-butyl, sec-butyl, isobutyl, t-butyl, pentyl isomers, hexyl isomers, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, and combinations thereof having 1-6 carbon atoms, etc. In some embodiments, the RXR agonist is an ethyl ester of formula I.
[0035] In some embodiments, the RXR agonist is 3,7-dimethyl-6(S),7(S)-methano,7-[1,1,4,4-tetramethyl-1,2,3,4-tetrahydronaphth-7-yl]2(E),4(E)heptadienoic acid, also known as IRX4204, and has the following chemical structure: [ka]
[0036] Pharmaceutically acceptable salts of RXR agonists can also be used in the disclosed embodiments. Disclosed are compounds that have sufficient acidic, sufficient basic or both functional groups, thereby reacting with any of many organic or inorganic bases and inorganic and organic acids to form salts.
[0037] Acids commonly used to form acid addition salts from RXR agonists having a basic group are inorganic acids such as hydrochloric acid, hydrobromic acid, hydroiodic acid, sulfuric acid, phosphoric acid, etc., and organic acids such as p-toluenesulfonic acid, methanesulfonic acid, oxalic acid, p-bromophenylsulfonic acid, carbonic acid, succinic acid, citric acid, benzoic acid, acetic acid, etc. Examples of such salts include sulfate, pyrosulfate, bisulfate, sulfite, bisulfite, phosphate, monohydrogenphosphate, dihydrogenphosphate, metaphosphate, pyrophosphate, chloride, bromide, iodide, acetate, propionate, decanoate, caprylate, acrylate, formate, isobutyrate, caproate, heptanoate, propiolate, oxalate, malonate, succinate, suberate, sebacate, fumarate, maleate, butyne-1,4-dioate, hexyne- These include 1,6-dioate, benzoate, chlorobenzoate, methylbenzoate, dinitrobenzoate, hydroxybenzoate, methoxybenzoate, phthalate, sulfonate, xylenesulfonate, phenylacetate, phenylpropionate, phenylbutyrate, citrate, lactate, gamma-hydroxybutyrate, glycolate, tartrate, methanesulfonate, propanesulfonate, naphthalene-1-sulfonate, naphthalene-2-sulfonate, and mandelate.
[0038] Bases commonly used to form base addition salts from RXR agonists having an acidic group include, for example, hydroxides of alkali metals such as sodium, potassium and lithium; hydroxides of alkaline earth metals such as calcium and magnesium; hydroxides of other metals such as aluminum and zinc; ammonia, and, for example, unsubstituted or hydroxy-substituted mono-, di- or trialkylamines; dicyclohexylamine; tributylamine; pyridine; N-methyl, N-ethylamine; diethylamine; triethylamine; for example, mono-, biphenylamine; Examples of the amines include, but are not limited to, mono-, bis-, or tris-(2-hydroxy lower alkylamines), for example, N,N-di-lower alkyl-N-(hydroxy lower alkyl)amines or tri-(2-hydroxyethyl)amine, such as N,N-dimethyl-N-(2-hydroxyethyl)amine; organic amines, such as N-methyl-D-glucamine; and amino acids, such as, for example, arginine and lysine.
[0039] IRX4204, like some other RXR ligands, does not activate non-permissive heterodimers such as RAR / RXR. However, IRX4204 is unique in that it specifically activates Nurr1 / RXR heterodimers and does not activate other permissive RXR heterodimers such as PPAR / RXR, FXR / RXR and LXR / RXR. Other RXR ligands generally activate these permissive RXR heterodimers. Therefore, all RXR ligands cannot be classified as belonging to one class. IRX4204 belongs to a unique class of RXR ligands that specifically activates only Nurr1 / RXR heterodimer, which is one of RXR homodimers and permissive RXR heterodimers. IRX4204 and its salts and esters are also called the method of activating Nurr1 / RXR heterodimer receptors or the rexinoid method of inhibiting tumor growth. In the aqueous environment of the body, IRX4204 free acid and its salts and esters are all expected to yield the same anionic species, albeit with potentially different reaction kinetics, and have similar physiological and therapeutic effects. Thus, any general reference to IRX4204 herein should be construed to include salts and esters, unless the context clearly dictates otherwise.
[0040] In one embodiment, the selective RXR agonist does not appreciably activate the permissive heterodimers PPAR / RXR, FXR / RXR and LXR / RXR. In another embodiment, the selective RXR agonist activates the permissive heterodimer Nurr1 / RXR. One example of such a selective RXR agonist is 3,7-dimethyl-6(S),7(S)-methano,7-[1,1,4,4-tetramethyl-1,2,3,4-tetrahydronaphthal-7-yl]2(E),4(E)heptadienoic acid (IRX4204), the structure of which is shown in formula II. In other aspects of this embodiment, activation of the permissive heterodimers PPAR / RXR, FXR / RXR, or LXR / RXR by an RXR agonist is 1% or less, 2% or less, 3% or less, 4% or less, 5% or less, 6% or less, 7% or less, 8% or less, 9% or less, or 10% or less than the ability of a non-RXR receptor activating agonist to activate the same permissive heterodimer. Examples of RXR agonists that activate one or more of PPAR / RXR, FXR / RXR, or LXR / RXR include LGD1069 (bexarotene) and LGD268.
[0041] Binding specificity refers to the ability of an RXR agonist to discriminate between an RXR receptor and a receptor that does not contain the binding site for the RXR agonist, such as the RAR receptor.
[0042] Certain embodiments provide a method of treating cancer comprising administering to a patient in need thereof an RXR agonist at a level below the RAR activation threshold and at or above the RXR activation threshold.
[0043] About IRX4204, RAR EC 10 (effective concentration to induce 10% of the maximum activity of RAR) is 300 nM for the α isoform and 200 nM for the β and γ isoforms. Thus, in some embodiments, concentrations not exceeding 200 nM are considered to be below the RAR activation concentration. For IRX4204, the RXR EC 90(effective concentration to induce 90% of maximal activity of RXR) is 0.1 nM for the α and γ isoforms and 1 nM for the β isoform. Thus, in some embodiments, a concentration of at least 0.1 nM is considered to exceed the RXR activation threshold. Based on human studies, 20 mg / m 2 Oral doses of IRX4204 per day result in systemic concentrations that remain below 200 nM. Similarly, 0.01-0.02 mg / m 2 Oral doses in the range of 0.1 nM or more per day are estimated to result in systemic concentrations of 0.1 nM or more. Thus, in various embodiments, the dose of IRX4204 is at least 0.01, 0.02, 0.03, 0.05, 0.1, 0.3, 0.5, 1, 3 or 5 mg / m 2 / day and 150, 200 or 300 mg / m 2 / day, or a range bounded by a combination of these values.
[0044] In other embodiments, the dosage of an RXR agonist, e.g., IRX4204, for an adult human is 0.2 to 300 mg / day, and in each embodiment, 0.5, 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10 mg / day, but not exceeding 10, 15, 20, 50 or 100 mg / day, or a range bounded by any combination of these values.
[0045] The RXR agonist can be administered to a mammal using standard administration techniques, including parenteral, oral, intravenous, intraperitoneal, subcutaneous, pulmonary, transdermal, intramuscular, intranasal, buccal, sublingual, or suppository administration. The term "parenteral" as used in this disclosure includes intravenous, intramuscular, subcutaneous, rectal, vaginal, and intraperitoneal administration. The RXR agonist is preferably suitable for oral administration, for example as a pill, tablet, or capsule. Administration may be continuous or intermittent. In certain embodiments, the total number of daily administrations of the RXR agonist can be a single administration or two administrations in a 24-hour period, with an interval of 8 to 16 hours or 10 to 14 hours.
[0046] (Thyroid Hormones) Both biologically derived and synthetic thyroid hormones have been used in medicine. The major forms of thyroid hormones are called T3 (triiodothyronine) and T4 (thyroxine). Thyroxine is less active but has a long half-life and is sometimes considered a prohormone of triiodothyronine. As used in this disclosure, the term "thyroid hormone" refers to both thyroxine and triiodothyronine. Thyroxine (thyroid hormone T4, levothyroxine sodium) is a tyrosine-based hormone produced by the thyroid gland and is primarily involved in regulating metabolism. Both are widely available commercially and suitable for use in the embodiments of the present disclosure. However, levothyroxine, a synthetic form of T4, is much more commonly utilized in clinical practice (except for patients who cannot convert T4 to T3) because its long half-life in the body facilitates once-daily administration. In some embodiments, the thyroid hormone administered is specifically thyroxine. In some embodiments, the thyroid hormone administered is triiodothyronine.
[0047] Administration of RXR agonists or their esters can result in suppression of serum thyroid hormones, potentially resulting in clinical hypothyroidism and associated disorders. However, in some embodiments, thyroid hormones are not co-administered (or are not co-administered initially) to improve suppression of serum thyroid hormone levels. Co-administration of thyroid hormones and RXR agonists improves the anti-cancer effects of RXR agonists, possibly through multiple mechanisms of action, compared to the effects of RXR agonists alone. Co-administered thyroid hormones can also reduce the hypothyroidism-inducing effects of RXR agonists, thereby improving the clinical safety and tolerability of the treatment. Thus, in preferred embodiments, thyroid hormones are co-administered with RXR agonists to enhance the effects of the treatment, regardless of whether administration of the RXR agonist has caused or is expected to cause clinical hypothyroidism. Administering thyroid hormones in concert or in combination with RXR agonists means that the respective administration methods of these two drugs are such that the physiological effects of the two drugs overlap in time. This does not require that the RXR agonist and the thyroid hormone be contained in the same composition or formulation, or be administered as separate compositions at the same time, by the same route of administration, or on the same schedule, although in some embodiments they may be any of the foregoing.
[0048] Suitable thyroxine dosages are generally from about 5 μg / day to about 250 μg / day administered orally initially, with the dosage increased every 2-4 weeks as needed. In other embodiments, suitable thyroxine dosages are from about 5 μg / day to about 225 μg / day, from about 7.5 μg / day to about 200 μg / day, from about 10 μg / day to about 175 μg / day, from about 12.5 μg / day to about 150 μg / day, from about 15 μg / day to 125 μg / day, from about 17.5 μg / day to about 100 μg / day, from about 20 μg / day to about 100 μg / day, or from about 20 μg / day to about 100 μg / day. μg / day, about 22.5 to about 100 μg / day, about 25 μg / day to about 100 μg / day, about 5 μg / day to about 200 μg / day, about 5 μg / day to about 100 μg / day, about 7.5 μg / day to about 90 μg / day, about 10 μg / day to about 80 μg / day, about 12.5 μg / day to about 60 μg / day, about 15 μg / day to about 50 μg / day. Dosage escalation is generally at about 5 μg / day, about 7.5 μg / day, about 10 μg / day, about 12.5 μg / day, about 15 μg / day, about 20 μg / day, or about 25 μg / day. In certain embodiments, an appropriate thyroid hormone dosage is one that produces a serum level of T4 in the upper 50%, upper 60%, upper 70%, upper 80%, or upper 90% of the normal range within a laboratory. Normal ranges for T4 levels may vary by laboratory, and target T4 levels are based on the normal range determined for each particular laboratory.
[0049] For each embodiment including a combination of an RXR agonist and a taxane, there are analogous embodiments in which such combination further includes a thyroid hormone.
[0050] (Taxane) Taxanes are classified as antitumor drugs, specifically as antimitotic and antimicrotubule drugs. Taxanes prevent the proliferation of cancer cells by blocking mitosis. They also induce apoptosis, resulting in cell death. Taxanes that have received marketing approval for the treatment of cancer include paclitaxel and docetaxel. As used herein, the term taxane refers to compounds that have both structural features associated with taxanes and antitumor activity.
[0051] Paclitaxel (CAS number: 33069-62-4) has the following structure: [ka] .
[0052] Docetaxel (CAS number: 114977-28-5) has the following structure: [ka]
[0053] Paclitaxel and docetaxel constitute a method of inducing apoptosis by binding tubulin and inhibiting microtubule disassembly, blocking metaphase spindle formation, or blocking Bcl-2-mediated inhibition of apoptosis.
[0054] Taxanes are typically administered by intravenous infusion at intervals of 2 to 3 weeks depending on the cancer being treated. Docetaxel is typically administered at a dose of 100 mg / mL per 1000 mg of body surface area. 2 Paclitaxel is typically administered at a dose of 75 mg per square meter of body surface area. 2 Other details of using these drugs in the treatment of cancer, including prior treatment, the use of other drugs, modified doses, etc., are known to those of skill in the art, and can be found, for example, prescribing information for paclitaxel at https: / / wwwDOTaccessdataDOTfdaDOTgov / drugsatfda_docs / label / 2011 / 020262s049lbl.pdf and prescribing information for docetaxel at https: / / wwwDOTaccessdataDOTfdaDOTgov / drugsatfda_docs / label / 2020 / 020449s084lbl.pdf, both of which are incorporated by reference in their entireties.
[0055] (combination) Further embodiments include combinations comprising an RXR agonist and a taxane as described herein. Some embodiments further comprise a thyroid hormone. Due to the different chemical nature of these drugs, potentially different routes of administration and / or administration schedules, these drugs are not necessarily co-formulated, although in some embodiments, these drugs may be co-formulated. These drugs may be combined in the sense that they are provided together by a pharmacy or a medical professional (such as a physician, physician assistant, etc.). These drugs may also constitute a combination by being administered and present simultaneously in the patient's body.
[0056] Further embodiments include kits containing the drug combinations described above. The kits may further include solvents, diluents, injectors, etc. that may facilitate administration of one or more therapeutic agents. The kits may further include instructions for the coordinated use of the therapeutic agents utilized in the disclosed methods, regardless of whether any particular agent is provided in the kit.
[0057] Pharmaceutical Compositions and Formulations The various active pharmaceutical ingredients used in the treatment described in this disclosure are typically present as pharmaceutical compositions or formulations. Such compositions or formulations may be liquid, semi-solid or solid formulations. The formulations of this disclosure may be prepared in a manner that forms one phase, such as an oil or a solid. Alternatively, the formulations of this disclosure may be prepared in a manner that forms two phases, such as an emulsion. The pharmaceutical compositions of this disclosure intended for such administration may be prepared according to any method known in the art for the manufacture of pharmaceutical compositions.
[0058] Liquid preparations suitable for parenteral injection or nasal spray may include physiologically acceptable sterile aqueous or non-aqueous solutions, dispersions, suspensions or emulsions, and sterile powders for reconstitution into sterile injectable solutions or dispersions. Preparations suitable for nasal administration may include physiologically acceptable sterile aqueous or non-aqueous solutions, dispersions, suspensions or emulsions. Examples of suitable aqueous and non-aqueous carriers, diluents, solvents or vehicles include water, ethanol, polyols (such as propylene glycol, polyethylene glycol (PEG), glycerol, etc.), suitable mixtures thereof, vegetable oils (such as olive oil), and injectable organic esters such as ethyl oleate. Proper fluidity can be maintained, for example, by the use of a coating such as lecithin, by maintaining the required particle size in the case of dispersions, and by the use of surfactants.
[0059] The pharmaceutical compositions of the present disclosure may optionally include a pharma- ceutically acceptable carrier that facilitates processing of the active compound into a pharma- ceutically acceptable composition. As used in this disclosure, the term "pharmaceutically acceptable" means a compound, material, composition and / or dosage form that, within the scope of sound medical judgment, is suitable for contact with human and animal tissues without undue toxicity, irritation, allergic response or other problem complications commensurate with a reasonable benefit / risk ratio. This definition also applies to the phrase "pharmaceutically acceptable salts thereof". As used in this disclosure, the term "pharmaceutically acceptable carrier" is synonymous with "pharmaceutical carrier" and refers to any carrier that produces substantially no long-term or permanent adverse effects when administered, and includes terms such as pharma- ceutical acceptable vehicles, stabilizers, diluents, additives, adjuvants or excipients. Such carriers are generally acceptable for mixing with, diluting or encapsulating the active compound, and may be solid, semi-solid or liquid medicines. It is understood that the active compound may be soluble or may be delivered as a suspension in the desired carrier or diluent. Any of a variety of pharma- ceutically acceptable carriers can be used, including, but not limited to, aqueous media such as water, saline, glycine, hyaluronic acid, and the like; solid carriers such as starch, magnesium stearate, mannitol, sodium saccharin, talc, cellulose, glucose, sucrose, lactose, trehalose, magnesium carbonate, and the like; solvents; dispersion media; coatings; antibacterial and antifungal agents; isotonic and absorption delaying agents; and any other inactive ingredients. The choice of pharma-ceutically acceptable carrier can depend on the mode of administration. Except where a pharma-ceutically acceptable carrier is incompatible with the active compound, its use in a pharma-ceutically acceptable composition is contemplated. Non-limiting examples of the specific uses of such pharmaceutical carriers include those described in Pharmaceutical Dosage Forms and Drug Delivery Systems (Howard C. Ansel et al. eds, Lippincott Williams & Wilkins Publishers, 7 thed. 1999); Remington: The Science and Practice of Pharmacy (Alfonso R. Gennaro ed., Lippincott, Williams & Wilkins, 20 th ed. 2000); Goodman & Gilman's The Pharmacological Basis of Therapeutics (Joel G. Hardman et al. eds, McGraw-Hill Professional, 10 th ed. 2001); and Handbook of Pharmaceutical Excipients (Raymond C. Rowe et al., APhA Publications, 4 th edition 2003. These protocols are prescribed and any modifications are within the scope of those skilled in the art and well within the scope of the teachings of this disclosure.
[0060] The pharmaceutical compositions of the present disclosure may optionally contain other pharma- ceutically acceptable ingredients (or pharmaceutical components), including, but not limited to, buffers, preservatives, isotonicity agents, salts, antioxidants, osmolality adjusters, bioactive substances, pharmacologically active substances, bulking agents, emulsifiers, wetting agents, sweeteners or flavoring agents, and the like. Various buffers and pH adjustment methods can be used in the preparation of the pharmaceutical compositions of the present disclosure, provided that the resulting preparation is pharma- ceutically acceptable. Such buffers include, but are not limited to, acetate buffers, borate buffers, citrate buffers, phosphate buffers, neutral buffered saline, and phosphate buffered saline. It is understood that acids or bases can be used to adjust the pH of the composition, as needed. Pharmaceutically acceptable antioxidants include, but are not limited to, sodium disulfite, sodium thiosulfate, acetylcysteine, butylated hydroxyanisole, and butylated hydroxytoluene. Useful preservatives include, but are not limited to, benzalkonium chloride, chlorobutanol, thimerosal, phenylmercuric acetate, phenylmercuric nitrate, stabilized oxychloro compositions such as, for example, sodium chlorite, and chelating agents such as, for example, DTPA or DTPA-bisamide, calcium DTPA and CaNaDTPA-bisamide. Isotonicity agents useful in the pharmaceutical compositions include, but are not limited to, salts such as, for example, sodium chloride, potassium chloride, mannitol or glycerin, and other pharma- ceutically acceptable isotonicity agents. The pharmaceutical compositions may be provided as salts, and can be formed with many acids, including, but not limited to, hydrochloric acid, sulfuric acid, acetic acid, lactic acid, tartaric acid, malic acid, succinic acid, and the like. Salts tend to be more soluble in aqueous or other protic solvents than the corresponding free base forms. It is understood that these and other materials known in the pharmaceutical arts can be included in the pharmaceutical compositions useful in the present invention.
[0061] Pharmaceutical formulations adapted for administration by inhalation include fine particle dusts or mists, which may be generated by means of various types of metered dose pressurized aerosols, nebulizers or insufflators.
[0062] Semi-solid formulations suitable for topical administration include, but are not limited to, ointments, creams, salves and gels. In such solid formulations, the active compound may be mixed with at least one inert conventional excipient (or carrier), such as lipids and / or polyethylene glycol.
[0063] Solid formulations suitable for oral administration include capsules, tablets, pills, powders, and granules. In such solid formulations, the active compound may be admixed with at least one inert conventional excipient (or carrier) such as sodium citrate or dicalcium phosphate or the like or (a) fillers or extenders, such as starch, lactose, sucrose, glucose, mannitol and silicic acid; (b) binders, such as carboxymethylcellulose, alginates, gelatin, polyvinylpyrrolidone, sucrose and acacia; (c) humectants, such as glycerol; (d) disintegrating agents, such as agar-agar, calcium carbonate, potato or tapioca starch, alginic acid, certain complex silicates and sodium carbonate; (e) solution retardants, such as paraffin; (f) absorption accelerators, such as quaternary ammonium compounds; (g) wetting agents, such as cetyl alcohol and glycerol monostearate; (h) adsorbents, such as kaolin and bentonite; and (i) lubricants, such as talc, calcium stearate, magnesium stearate, solid polyethylene glycols, sodium lauryl sulfate or mixtures thereof. In the case of capsules, tablets and pills, the dosage forms may also comprise buffering agents.
[0064] The small molecule components of various embodiments, i.e., RXR agonist and thyroid hormone, can be formulated into solid oral dosage forms.Taxane components are generally formulated as liquids for intravenous infusion.In other embodiments, taxane components can be provided in lyophilized form for reconstitution as liquid locally at treatment site, typically intravenously injecting into patients.
[0065] The antibody component is generally formulated as a liquid, typically for intravenous infusion. In other embodiments, the antibody component may be provided in lyophilized form for reconstitution as a liquid locally at the treatment site, typically intravenously infused into the patient. While intravenous infusion is typical, in other embodiments, the antibody may be administered by another route of administration, such as subcutaneous injection or infusion.
[0066] (treatment) The terms "treatment", "treating" and the like as used in this disclosure refer to obtaining a desired pharmacological and / or physiological effect. This may be directly observed as a slowdown in tumor growth, a stable or partial or complete response (i.e., tumor shrinkage or tumor elimination), or an increase in overall or disease-free survival. Treatment may also be observed as an improvement or alleviation of symptoms associated with the underlying cancer. However, as a cancer treatment, the purpose and mechanism of action of the disclosed embodiments is targeted to inhibit, stabilize or reduce tumor growth (including tumor metastasis), or to partially or completely eliminate the tumor, or to increase overall or disease-free survival, with effects on other cancer symptoms being secondary. Such direct treatment of other symptoms (e.g., pain, nausea, loss of appetite, etc.) is not within the scope of cancer treatment as used in this disclosure. That is, treating a cancer patient's symptoms, e.g., cachexia, is not treating the cancer. However, agents that treat cancer (e.g., affect cancer growth and / or metastasis) may also improve symptoms such as cachexia, either indirectly through their effects on cancer, or directly through pleiotropic effects. A "therapeutically effective amount" refers to an amount effective to obtain the desired therapeutic result, at the dosage and duration required. The therapeutically effective amount may vary depending on factors such as disease state, age, sex, weight, and the ability of the Her2 targeted therapeutic, RXR agonist, and thyroid hormone, if used, to elicit the desired response in an individual.
[0067] However, the dosage administered to a mammal, particularly a human, in the context of the present method should be sufficient to effect therapeutic response in the mammal within a reasonable time frame.Those skilled in the art will recognize that the exact dosage and composition and the selection of the most suitable delivery regimen are also influenced by, among other things, the pharmacological properties of the formulation, the nature and severity of the disease being treated and the physical condition and mental acuity of the patient, and the potency of the specific compound, the age, disease, weight, sex and response of the patient being treated and the stage / severity of the disease.
[0068] Therapeutic activities include administration of the pharmaceuticals, dosage forms and pharmaceutical compositions described herein to a patient, whether by a medical professional, the patient himself or any other person, particularly in accordance with the various treatment methods described herein. Therapeutic activities include orders, instructions and advice from medical practitioners, such as physicians, physician assistants, nurses, etc., which are then carried out by any other person, including other medical practitioners or the patient himself. In some embodiments, therapeutic activities may also include recommending, inducing or mandating that a particular pharmaceutical or combination of pharmaceuticals be selected for the treatment of a disease and that the pharmaceuticals are actually used, such as by insurance companies or pharmacy benefit management companies, approving coverage for a pharmaceutical, denying coverage for an alternative pharmaceutical, including a pharmaceutical in an adopted formulary or excluding an alternative pharmaceutical, or providing financial incentives to use a pharmaceutical. In some embodiments, therapeutic activities may also include recommending, inducing or mandating that a particular pharmaceutical is selected for the treatment of a disease and that the pharmaceuticals are actually used, such as by policies or practice standards, such as those established by hospitals, clinics, health maintenance organizations, medical practices or physician groups.
[0069] To benefit from the combined effects of the RXR agonist of formula I (or a pharma- ceutically acceptable salt or ester thereof) and a taxane, embodiments include administering to Her2 +The present invention includes a method of treating a patient with cancer, the method comprising or consisting of administering an RXR agonist of formula I (or a pharma- ceutically acceptable salt thereof) and a taxane. Some embodiments further comprise administering a thyroid hormone in coordination with the administration of the RXR agonist. In some embodiments, Her2 + Cancer is Her2 + In some embodiments, the cancer is Her2 + Cancer is Her2 + Gastroesophageal cancer, ovarian cancer, gastric cancer, lung adenocarcinoma, uterine cancer (such as serous endometrial cancer), or salivary duct cancer. Some embodiments specifically include one or more of these cancers. Other embodiments specifically exclude one or more of these cancers.
[0070] In various embodiments, the therapeutic methods of the present disclosure may be applied as a primary treatment, as a debulking therapy prior to surgical removal of the tumor, or as an adjuvant therapy following any form of primary treatment (particularly surgery) to address residual disease and / or reduce the risk of cancer recurrence.
[0071] In some embodiments, Her2 + The patient with cancer has not been previously treated with either an RXR agonist of formula I (or a pharma- ceutically acceptable salt thereof) or a taxane. In some embodiments, the patient has been previously treated with an RXR agonist of formula I (or a pharma- ceutically acceptable salt thereof) and has achieved stable disease or a partial response (in some embodiments, as defined by RECIST or iRECIST criteria), i.e., the cancer is sensitive to an RXR agonist of formula I (or a pharma- ceutically acceptable salt thereof), and the taxane is added to the treatment regimen. In some embodiments, the patient has been previously treated with a taxane and has achieved stable disease or a partial response (in some embodiments, as defined by RECIST or iRECIST criteria), i.e., the cancer is sensitive to a taxane, and the taxane is added to the treatment regimen.
[0072] Thus, some embodiments provide a method for treating Her2 + The present invention includes administering RXR agonist to the patient with tumor. Some embodiments include administering RXR agonist to the patient who has had some therapeutic effect (less than complete response) with taxane, i.e., administering RXR agonist is added to the treatment regimen of taxane. Some embodiments include administering taxane to the patient who has had some therapeutic effect (less than complete response) with RXR agonist (or RXR agonist in combination with thyroid hormone), i.e., administering taxane is added to the treatment regimen of RXR agonist.
[0073] The effectiveness of treatment can be monitored by periodic evaluation of the treated patient. For repeated administration over a period of several days or more, treatment can be repeated until the desired suppression of disease or condition occurs. However, other administration regimes may be useful and are within the scope of this disclosure. Antibodies typically have a much longer half-life in the body than other active agents used in these methods, and therefore the interval between administrations is typically much longer (weeks).
[0074] The effectiveness of cancer treatments is usually measured in terms of "response." Techniques to monitor response can be similar to tests used to diagnose cancer, including, but not limited to: Lumps or tumors involving lymph nodes can be seen and evaluated externally during a medical exam. Some internal cancer tumors can be seen with an x-ray or CT scan and measured with a ruler. Blood tests, including measurements of organ function, may be performed. For certain cancers, tumor marker tests may be performed.
[0075] Regardless of the test used -- blood tests, cell counts, or tumor marker tests -- it is repeated at specific intervals so that results can be compared with previous tests of the same type.
[0076] Response to cancer treatment is defined in several ways. Complete Response: All of the cancer or tumor has disappeared and you are living without disease. Tumor marker levels (if applicable) may remain within normal ranges. Partial Response: The cancer has shrunk by some percentage, but disease remains. Tumor marker (if applicable) levels may have decreased (or increased, based on the tumor marker, as a sign of decreased tumor burden), but evidence of disease remains. Stable disease: The cancer is not growing or shrinking, there is no change in the disease, and there is no significant change in tumor markers (if applicable). Progression: The cancer is growing and the disease is worse than before treatment. Tumor marker testing (if applicable) shows an increase in tumor markers.
[0077] Other endpoints of efficacy of cancer treatment include the intervals of overall survival (i.e., the time from diagnosis or initiation of evaluated treatment to death from any cause), cancer-free survival (i.e., the period following a complete response during which no cancer is detectable), and progression-free survival (i.e., the period following stable disease or partial response during which no recurrence of tumor growth is detectable).
[0078] There are two standard methods for evaluating the efficacy of treatment of solid cancers in terms of tumor size (tumor burden): the WHO criteria and the RECIST criteria. These methods involve measuring solid tumors and modifying treatment regimens to compare current tumors with past measurements or to compare changes with future measurements. In the WHO method, the long and short axes of solid tumors are measured and their products are calculated. If there are multiple solid tumors, the sum of all products is calculated. In the RECIST method, only the long axis is measured. If there are multiple solid tumors, the sum of all long axis measurements is calculated. However, for lymph nodes, the short axis is measured instead of the long axis. There is also a RECIST method for immunotherapy (iRECIST), which takes into account the unique behavior associated with this type of therapeutic agent, such as delayed response after pseudo-progression. Both the RECIST 1.1 guideline and the iRECIST guideline are incorporated by reference in their entirety into this disclosure.
[0079] In some embodiments of the methods of the present disclosure, the tumor burden in a treated patient is reduced by about 5%, about 10%, about 15%, about 20%, about 25%, about 30%, about 35%, about 40%, about 45%, about 50%, about 55%, about 60%, about 65%, about 70%, about 75%, about 80%, about 90%, about 95%, about 100%, or a range bounded by these values.
[0080] In other embodiments, the one-year survival rate of treated subjects is increased by about 5%, about 10%, about 15%, about 20%, about 25%, about 30%, about 35%, about 40%, about 45%, about 50%, about 55%, about 60%, about 65%, about 70%, about 75%, about 80%, about 90%, about 95%, about 100%, or a range bounded by these values.
[0081] In other embodiments, the 5-year survival rate of treated subjects is increased by about 5%, about 10%, about 15%, about 20%, about 25%, about 30%, about 35%, about 40%, about 45%, about 50%, about 55%, about 60%, about 65%, about 70%, about 75%, about 80%, about 90%, about 95%, about 100%, or a range bounded by these values.
[0082] In other embodiments, the 10-year survival rate of treated subjects is increased by about 5%, about 10%, about 15%, about 20%, about 25%, about 30%, about 35%, about 40%, about 45%, about 50%, about 55%, about 60%, about 65%, about 70%, about 75%, about 80%, about 90%, about 95%, about 100%, or a range bounded by these values.
[0083] In still other embodiments, the subject has sustained remission for at least 6 months, at least 7 months, at least 8 months, at least 9 months, at least 10 months, at least 11 months, at least 12 months, at least 14 months, at least 16 months, at least 18 months, at least 20 months, at least 22 months, at least 24 months, at least 27 months, at least 30 months, at least 33 months, at least 36 months, at least 42 months, at least 48 months, at least 54 months, or at least 60 months or more.
[0084] In other embodiments, the method can additionally help treat or alleviate cancer-related diseases, conditions or disorders.In some embodiments, these diseases or conditions include, but are not limited to, anemia, asthenia, cachexia, Cushing's syndrome, fatigue, gout, periodontal disease, hematuria, hypercalcemia, hypothyroidism, internal bleeding, hair loss, mesothelioma, nausea, night sweats, neutropenia, paraneoplastic syndrome, pleurisy, polymyalgia rheumatica, rhabdomyolysis, stress, lymphadenopathy, thrombocytopenia, vitamin D deficiency or weight loss.Cancer treatment can alleviate or treat associated conditions, but treating cancer-related conditions is not cancer treatment if tumors are not expected to shrink or disappear or to inhibit tumor growth or expansion.
[0085] Toxicity and adverse events are often graded on a five-point scale. Grade 1 or mild toxicity induces no symptoms or only mild symptoms; can be characterized by only clinical or diagnostic observations; and no therapeutic intervention is indicated. Grade 2 or moderate toxicity may impair activities of daily living (e.g., food preparation, shopping, money management, phone use), but only minimal, localized, or non-invasive therapeutic intervention is indicated. Grade 3 toxicity is medically significant but not immediately life-threatening; hospitalization or extended hospitalization is indicated and may impair activities of daily living related to self-care (e.g., bathing, dressing, eating, toileting, taking medication, and avoiding bedriddenness). Grade 4 toxicity is life-threatening and emergency therapeutic intervention is indicated. Grade 5 toxicity results in death associated with the adverse event. Thus, in various embodiments, the use of an RXR agonist or an RXR agonist and thyroid hormone reduces the grade of toxicity associated with the use of Her2-targeted therapy by allowing the use of lower doses without substantially sacrificing efficacy. In some embodiments, the use of an RXR agonist or an RXR agonist and thyroid hormone in combination with a Her2 targeted therapy reduces toxicity to Grade 1 or below or produces no toxicity findings without a substantial decrease in efficacy as would be expected from a Her2 targeted therapy alone. In some embodiments, the combination of a Her2 targeted therapy and an RXR agonist or an RXR agonist and thyroid hormone allows for continued use of a Her2 targeted therapy at a therapeutically effective low dose in cases where treatment with a Her2 targeted therapy would have to be discontinued due to unacceptable toxicity. In some of these embodiments, the Her2 targeted therapy comprises a Her2 kinase inhibitor.
[0086] The combination of the disclosed RXR agonist and Her2 targeted therapeutic agent produces synergistic effects. That is, they interact in a positive manner that produces greater inhibition of tumor cell growth than would be expected from the independent (non-interactive) effects of both. Thus, some embodiments produce improved efficacy. Other embodiments allow for reduced dosage to reduce toxicity while still achieving at least similar efficacy as provided by individual therapeutic agents. In some embodiments, both reduced toxicity and improved efficacy (compared to more toxic single agents) are achieved.
[0087] For each treatment, Her2 + Use of RXR agonists in combination with taxanes or taxanes and thyroid hormone to treat cancer; Her2 + Further similar embodiments exist for the above-described methods directed to the use of an RXR agonist in the manufacture of a medicament for use in combination with a taxane or a taxane and a thyroid hormone to treat cancer.
[0088] List of Specific Embodiments The following list of embodiments is illustrative of the various embodiments, with respect to scope, combinations and subcombinations, classifications of inventions, etc., described in this disclosure, but is not intended to be an exhaustive recitation of all embodiments supported by this disclosure.
[0089] Embodiment 1. A method of administering to a patient a taxane and an RXR agonist of formula I, or a pharma- ceutically acceptable salt thereof, comprising: [ka] In the formula, R is H or lower alkyl having 1 to 6 carbon atoms. method.
[0090] Embodiment 2. The method of embodiment 1, wherein the patient has not been previously treated with an RXR agonist but has been treated with a taxane and has had less than a complete response.
[0091] Embodiment 3. The method of embodiment 1, wherein the patient has not been previously treated with a taxane but has been treated with an RXR agonist and has had less than a complete response.
[0092] Embodiment 4. A method for treating Her2 in a patient in need of treatment. + 1. A method of treating cancer, comprising: A method of inducing apoptosis by binding tubulin and inhibiting microtubule disassembly, blocking metaphase spindle formation, or blocking Bcl-2-mediated inhibition of apoptosis, comprising administering to a patient an RXR agonist of formula I or a pharma- ceutical acceptable salt thereof, [ka] In the formula, R is H or lower alkyl having 1 to 6 carbon atoms. method.
[0093] Embodiment 5. A method for treating Her2 in a patient in need of treatment + 1. A method of treating cancer, comprising: A method comprising administering to a patient a taxane and a method of activating an RXR / Nurr1 heterodimer receptor or a rexinoid method of inhibiting tumor growth.
[0094] Embodiment 6 The method of any one of embodiments 1 to 5, further comprising administering a thyroid hormone.
[0095] Embodiment 7. The method of any one of embodiments 1-3 and 5-6, wherein the RXR agonist of formula I is a compound of formula II. [ka]
[0096] Embodiment 8. The method of any one of embodiments 1-4 and 6, wherein the taxane is paclitaxel.
[0097] Embodiment 9. The method of any one of embodiments 1-4 and 6, wherein the taxane is docetaxel.
[0098] Embodiment 10. Her2 + The method of any one of embodiments 1 to 9, wherein the cancer is gastroesophageal cancer, ovarian cancer, gastric cancer, lung adenocarcinoma, uterine cancer, or salivary duct cancer.
[0099] Embodiment 11. Her2 + Cancer is Her2 + The method of any one of embodiments 1 to 9, wherein the cancer is breast cancer.
[0100] Embodiment 12. The method of any one of embodiments 1 to 11, wherein the combination of the taxane and the RXR agonist has a growth inhibitory effect that is greater than the additive growth inhibitory effect of each of the taxane and the RXR agonist alone.
[0101] Embodiment 13. The method of any one of embodiments 1 to 12, further comprising administration of an additional anticancer drug.
[0102] (Example) The following non-limiting examples are provided for illustrative purposes only to facilitate a more complete understanding of representative embodiments presently contemplated, and should not be construed as limiting any of the embodiments described in this disclosure.
[0103] Example 1 Evaluation of synergistic effects of IRX4204 and paclitaxel in combination in inhibiting tumor cell proliferation Her2 +AU565 human breast cancer cell lines were seeded at 500-3000 cells per well in 96-well plates and treated with paclitaxel [2.5, 5, or 10 nM] or DMSO (0.1%) in combination with IRX4204 [10, 100, or 1000 nM]. After 6-10 days of treatment, cells were fixed with 4% paraformaldehyde. Nuclei were stained with DAPI, imaged with a MetaXpress® microscope (Molecular Devices), and counted with CellReporterXpress® analysis software. Each data point represents the average of six replicates. The CV rate between replicates is less than 7%.
[0104] AU565 cells are sensitive to both single-agent paclitaxel and single-agent IRX4204. The combination of the two drugs inhibited proliferation to a greater extent than either drug alone (Figure 1). To evaluate whether the increased inhibition due to the drug combination was additive or synergistic, the combination index (CI) was calculated using the computer program CompuSyn (CompuSyn, Inc.). The results are shown in Table 1 and Figure 2.
[0105] Table 1: CI data for non-constant combinations (IRX4204 and paclitaxel) [Table 1]
[0106] A combination coefficient of approximately 1 indicates an additive effect, >1 indicates an antagonistic effect, and <1 indicates a synergistic effect. Thus, IRX4204 and paclitaxel showed synergistic effects at every point. The clustering of data points for each paclitaxel concentration in Figure 2 reflects the lack of a strong dose effect with IRX4204 in the concentration range tested, as IRX4204 was close to maximal at all concentrations. The data indicate that a stronger synergistic signal would be observed at lower concentrations of IRX4204.
[0107] Example 2 Evaluation of synergistic effects of IRX4204 and paclitaxel in inhibiting tumor cell growth using additional cell lines At the concentrations used in Example 1, IRX4204 had submaximal efficacy as a single agent at all concentrations, making it difficult to observe synergistic effects. Additional growth inhibition studies were performed on SkBr3 (Her2 + ) human breast cancer. IRX4204 was used at concentrations of 0, 0.00001, 0.0001, 0.001, 0.01, 0.1, 1.0, 10, 100, and 1000 nM, and paclitaxel was used at concentrations of 0, 2, 3, 6, 8, and 10 nM. + A synergistic effect was also observed for inhibition of cell line proliferation: the combination of the two drugs inhibited proliferation to a greater extent than either drug alone (Figure 3). Figure 4 shows that all concentrations of paclitaxel exhibited synergistic effects with IRX4204.
[0108] Further growth inhibition studies were performed on additional cancer cell lines (ZR751 (Her2 + ), MDAMB231(Her2 - ), MCF7(Her2 - ) human breast cancer, and MMTV-ErbB2 clone #7A-99 (Her2 + ) mouse breast cancer). IRX4204 is used at lower concentrations, including 0.1 nM and 1.0 nM. + A synergistic effect is observed in inhibiting the proliferation of the cell lines.
[0109] Finally, although aspects of the present disclosure are highlighted by reference to specific embodiments, those skilled in the art will readily appreciate that these disclosed embodiments are merely illustrative of the principles of the subject matter of the present disclosure. Therefore, it should be understood that the disclosed subject matter is in no way limited to the specific methodology, protocols and / or reagents, etc. described in the present disclosure. Thus, various modifications or configuration changes or substitutions of the disclosed subject matter can be made in accordance with the teachings of the present disclosure without departing from the spirit of the present disclosure. Finally, the terms used in the present disclosure are for the purpose of describing specific embodiments only, and are not intended to limit the scope of the present invention, which is defined solely by the claims. Thus, the present invention is not limited to what has been precisely shown and described.
[0110] Certain embodiments of the present invention have been described in this disclosure, including the best mode known to the inventors for carrying out the invention. Of course, variations on these described embodiments will become apparent to those skilled in the art upon reading the foregoing description. The inventors expect that such variations will be adopted by those skilled in the art as appropriate, and the inventors intend for the invention to be practiced otherwise than as specifically described in this disclosure. Accordingly, this invention includes all modifications and equivalents of the subject matter recited in the claims appended to this disclosure as permitted by applicable law. Moreover, any combination of the above-described embodiments in all possible variations thereof is encompassed by the present invention unless otherwise indicated in this disclosure or clearly contradicted by context.
[0111] Groupings of alternative embodiments, elements or steps of the invention are not to be construed as limitations. Each group member may be referenced and claimed individually or in any combination with other group members disclosed in this disclosure. It is anticipated that one or more members of a group may be included in, or deleted from, a group for reasons of convenience and / or patentability. When such inclusions or deletions are made, the present disclosure will be deemed to include the modified group and therefore will satisfy all Markush group recitations used in the appended claims.
[0112] Unless otherwise indicated, all numerical values expressing properties, items, quantities, parameters, characteristics, terms, etc. used in the present disclosure and claims shall be understood in all instances to be modified by the term "about". When used in this disclosure, the term "about" means that the property, item, quantity, parameter, characteristic or term so modified encompasses a range of plus or minus 10 percent above or below the value of the stated property, item, quantity, parameter, characteristic or term. Thus, unless indicated to the contrary, the numerical parameters set forth in this disclosure and the appended claims are approximations that may vary. At the very least, and without intending to limit the application of the doctrine of equivalents to the scope of the claims, each numerical indication should be construed, at the very least, in light of the number of reported significant digits and by applying ordinary rounding techniques. Notwithstanding that the numerical ranges and values setting forth the broad scope of the invention are approximations, the numerical ranges and values set forth in the specific examples are reported as precisely as possible. However, any numerical range or value inherently contains certain errors necessarily resulting from the standard deviation found in each testing measurement. The recitation of numerical ranges in this disclosure is merely intended to serve as a shorthand method of referring individually to each separate value falling within that range. Unless otherwise indicated in the disclosure, each separate value in a numerical range is incorporated into this disclosure as if it were individually set forth in the disclosure.
[0113] The terms "a," "an," "the," and similar reference words used in the context of describing the present invention (particularly in the context of the claims below) shall be construed to encompass both the singular and the plural, unless otherwise indicated in the disclosure or clearly contradicted by context. All methods described in this disclosure can be performed in any suitable order, unless otherwise indicated in the disclosure or clearly contradicted by context. The use of any and all examples or exemplary language (e.g., "such as") provided in this disclosure is intended merely to better illuminate the invention and does not pose a limitation on the scope of the invention as otherwise claimed. No language in this disclosure should be construed as indicating any non-claimed element essential to the practice of the invention.
[0114] Certain embodiments disclosed in this disclosure may be further limited in the claims using the phrase "consisting of" or "consisting essentially of." When used in the claims, whether as filed or added by amendment, the transitional phrase "consisting of" excludes any element, step, or ingredient not specified in the claim. The transitional phrase "consisting essentially of" limits the scope of the claim to those materials or steps specified and which do not materially affect the basic and novel characteristic(s). The embodiments of the invention so claimed are essentially or explicitly described and embodied in this disclosure.
[0115] All patents, patent publications and other publications referenced or identified in this disclosure are individually and expressly incorporated by reference in their entirety into this disclosure, for example, for the purpose of describing and disclosing the compositions and methodologies described in such publications that may be used in connection with the present invention. These publications are provided solely for their disclosure prior to the filing date of this application. Nothing in this regard should be construed as an admission that the inventors are not entitled to antedate such disclosure by virtue of prior invention or for any other reason. All statements as to the date or representation as to the contents of these documents are based on the information available to the applicant and do not constitute any admission as to the correctness of the dates or contents of these documents.
[0116] [Note] [Appendix 1] Her2 in patients who need treatment + 1. A method of treating cancer, comprising: administering to said patient a taxane and an RXR agonist of formula I or a pharma- ceutical acceptable salt thereof; [ka] In the formula, R is H or lower alkyl having 1 to 6 carbon atoms. method.
[0117] [Appendix 2] The method of claim 1, wherein the patient has not been previously treated with the RXR agonist but has been treated with the taxane and has had less than a complete response.
[0118] [Appendix 3] The method of claim 1, wherein the patient has not been previously treated with the taxane but has been treated with the RXR agonist.
[0119] [Appendix 4] Her2 in patients who need treatment + 1. A method of treating cancer, comprising: A method of inducing apoptosis by binding tubulin and inhibiting microtubule disassembly, blocking metaphase spindle formation, or blocking Bcl-2-mediated inhibition of apoptosis, comprising administering to said patient an RXR agonist of formula I or a pharma- ceutical acceptable salt thereof; [ka] In the formula, R is H or lower alkyl having 1 to 6 carbon atoms. method.
[0120] [Appendix 5] Her2 in patients who need treatment + 1. A method of treating cancer, comprising: administering to said patient a taxane and a method that activates an RXR / Nurr1 heterodimer receptor or a rexinoid to inhibit tumor growth.
[0121] [Appendix 6] 6. The method of any one of claims 1 to 5, further comprising administering a thyroid hormone.
[0122] [Appendix 7] The method of any one of claims 1 to 3, 5, and 6, wherein the RXR agonist of formula I is a compound of formula II. [ka]
[0123] [Appendix 8] The method of any one of appendixes 1 to 4 and 6, wherein the taxane is paclitaxel.
[0124] [Appendix 9] The method of any one of appendixes 1 to 4 and 6, wherein the taxane is docetaxel.
[0125] [Appendix 10] Her2 +10. The method of any one of claims 1 to 9, wherein the cancer is gastroesophageal cancer, ovarian cancer, gastric cancer, lung adenocarcinoma, uterine cancer, or salivary duct cancer.
[0126] [Appendix 11] Her2 + Cancer is Her2 + 10. The method of any one of claims 1 to 9, wherein the cancer is breast cancer.
[0127] [Appendix 12] 12. The method of any one of claims 1 to 11, wherein the combination of the taxane and the RXR agonist has a growth inhibitory effect that is greater than the additive growth inhibitory effect of each of the taxane and the RXR agonist alone.
[0128] [Appendix 13] 13. The method of any one of claims 1 to 12, further comprising administration of an additional anticancer drug.
Claims
1. Her2 in patients in need of treatment + 1. A method of treating cancer, comprising: administering to said patient a taxane and an RXR agonist of formula I or a pharma- ceutically acceptable salt thereof; 【Chemistry 1】 In the formula, R is H or lower alkyl having 1 to 6 carbon atoms. method.
2. 10. The method of claim 1, wherein the patient has not been previously treated with the RXR agonist but has been treated with the taxane and has had less than a complete response.
3. 10. The method of claim 1, wherein the patient has not been previously treated with the taxane but has been treated with the RXR agonist.
4. Her2 in patients in need of treatment + 1. A method of treating cancer, comprising: A method of inducing apoptosis by binding tubulin and inhibiting microtubule disassembly, blocking metaphase spindle formation, or blocking Bcl-2-mediated inhibition of apoptosis, comprising administering to said patient an RXR agonist of formula I or a pharma- ceutical acceptable salt thereof; 【Chemistry 2】 In the formula, R is H or lower alkyl having 1 to 6 carbon atoms. method.
5. Her2 in patients in need of treatment + 1. A method of treating cancer, comprising: administering to said patient a taxane and a method that activates the RXR / Nurr1 heterodimer receptor or a rexinoid to inhibit tumor growth.
6. 6. The method of any one of claims 1 to 5, further comprising administering a thyroid hormone.
7. 7. The method of any one of claims 1 to 3, 5, and 6, wherein the RXR agonist of formula I is a compound of formula II. 【Chemistry 3】
8. 7. The method of any one of claims 1 to 4 and 6, wherein the taxane is paclitaxel.
9. 7. The method of any one of claims 1 to 4 and 6, wherein the taxane is docetaxel.
10. Her2 + 10. The method of any one of claims 1 to 9, wherein the cancer is gastroesophageal cancer, ovarian cancer, gastric cancer, lung adenocarcinoma, uterine cancer, or salivary duct cancer.
11. Her2 + Cancer is Her2 + The method according to any one of claims 1 to 9, wherein the cancer is breast cancer.
12. 12. The method of any one of claims 1 to 11, wherein the combination of the taxane and the RXR agonist has a growth inhibitory effect that is greater than the additive growth inhibitory effect of each of the taxane and the RXR agonist alone.
13. 13. The method of any one of claims 1 to 12, further comprising administration of an additional anti-cancer drug.
Citation Information
Patent Citations
Treatment of cancer with specific RXR agonists
EP1937244A2
Treatment of cancer with combinations of RXR agonists and thyroid hormones
US20190365681A1
Use of an RXR agonist in treating her2+ cancers
WO2020251556A1
Bridged bicyclic aromatic compounds and their use in modulating gene expression of retinoid receptors
US5466861A
2,4-pentadienoic acid derivatives having retinoid-like biological activity
US5675033A
